FDA Approval Alert: The Need-to-Know

Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.

What Does Sevabertinib’s Expanded Approval Mean for HER2+ NSCLC?

ByXiuning Le, MD, PhD

October 5th 2026

Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.

The FDA’s decision on iberdomide is a “landmark approval” for those with multiple myeloma, according to Surbhi Sidana, MD.

Unpacking Iberdomide’s FDA Approval and The Future of CELMoDs

BySurbhi Sidana, MD

September 7th 2026

The FDA’s decision on iberdomide is a “landmark approval” for those with multiple myeloma, according to Surbhi Sidana, MD.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

ByGary Steinberg, MD

September 29th 2025

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

ByJorge Nieva, MD

July 14th 2025

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Trending on CancerNetwork

Which Head and Neck Cancer Data Should You Watch For at ESMO 2026?

Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer

Sofetabart Mipitecan Shows Activity Across FRα Expression Levels in PROC

Reducing Stigma and Nihilism Around Lung Cancer Screening and Diagnosis

Discussing Guidelines, New Data, and Earlier Referrals in Multiple Myeloma